Brought to you by 
TxCell completes €16.2mm IPO on Euronext Paris
21 Apr 2014
Executive Summary
TxCell SA (cellular immunotherapies) raised €16.2mm ($22.3mm) in its initial public offering on the Euronext Paris market. The company sold 2.9mm shares, less than the 3.9mm planned, at €5.58, the bottom end of its €5.58-6.82 price range.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
TxCell completes €16.2mm IPO on Euronext Paris
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice